Glucose metabolism disorders and the risk of cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 59, Issue 3, 2011, Pages 215-230

  Piątkiewicz, Paweł ^a   Czech, Anna ^a  

^a Brodnowski Hospital Warsaw   (Poland)

Author keywords

Cancer; Diabetes; Glucose; Insulin

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADIPOSE TISSUE; BREAST CANCER; CANCER RISK; CELL METABOLISM; CHRONIC INFLAMMATION; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; EPIDEMIC; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS CANCER; PROSTATE CANCER; REVIEW; RISK FACTOR; RISK REDUCTION; SKIN CANCER; STOMACH CANCER; TUMOR CELL;

EID: 79959243918     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-011-0119-0     Document Type: Review

References (190)

1. Adami HO, Chow WH, Nyrén O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472-1477 (Pubitemid 26340049)
2. Ahn J, Weinstein SJ, Snyder K et al (2006) No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 15: 2010-2012
3. Airley RE, Mobasheri A (2007) Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53:233-256 (Pubitemid 47074647)
4. Alexiou P, Chatzopoulou M, Pegklidou K et al (2010) RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 17:2232-2252
5. Atchison EA, Gridley G, Carreon JD et al (2011) Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 128: 635-643
6. Balato A, Unutmaz D, Gaspari AA (2009) Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J Invest Dermatol 129:1628-1642
7. Balkau B, Kahn HS, Courbon D et al (2001) Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care 24:843-849 (Pubitemid 33636056)
8. Barbarroja N, Lopez-Pedrera R, Mayas MD et al (2010) The obese healthy paradox: is inflammation the answer? Biochem J 430: 141-149
9. Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754-2764
10. Barone BB, Yeh HC, Snyder CF et al (2010) Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33:931-939
11. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297-336 (Pubitemid 46697911)
12. Bergamini E, Cavallini G, Donati A et al (2007) The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction. Ann NY Acad Sci 1114:69-78 (Pubitemid 350070387)
13. Berzofsky JA, Terabe M (2009) The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 9:667-672
14. Biassoni R (2009) Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol Chapter 14:Unit 14.10
15. Blüher M (2009) Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 117:241-250
16. Blüher M (2010) The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 21:38-43
17. Boden G (2009) Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation? Diabetes 58:518-519
18. Borugian MJ, Spinelli JJ, Sun Z et al (2007) Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16:2164-2165 (Pubitemid 47621196)
19. Boulle N, Logié A, Gicquel C et al (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83:1713-1720 (Pubitemid 28501047)
20. Bowker SL, Majumdar SR, Veugelers P (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258 (Pubitemid 44106500)
21. Bowker SL, Yasui Y, Veugelers P et al (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631-1637
22. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625
23. Bustamante E, Morris HP, Pedersen PL (1981) Energy metabolism of tumor cells.Requirement for a form of hexokinasewith a propensity for mitochondrial binding. J Biol Chem 256:8699-8704 (Pubitemid 12254812)
24. Buzzai M, Jones RG, Amaravadi RK et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752 (Pubitemid 47105521)
25. Cai W, He JC, Zhu L et al (2004) High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 110:285-291 (Pubitemid 38955497)
26. Cannata D, Fierz Y, Vijayakumar A et al (2010) Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 77:197-213
27. Chan AC, Serwecinska L, Cochrane A et al (2009) Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family. Clin Exp Immunol 156:238-245
28. Chodick G, Heymann AD, Rosenmann L et al (2010) Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21:879-887
29. Chong CR, Chabner BA (2009) Mysterious metformin. Oncologist 14:1178-1181
30. Christofk HR, Vander Heiden MG, Harris MH et al (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-233 (Pubitemid 351380249)
31. Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765
32. Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081
33. Considine RV, Sinha MK, Heiman ML et al (1996) Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295 (Pubitemid 26033933)
34. Corleta HE, Capp E, Corleta OC (1996) Insulin receptor tyrosine kinase activity in colon carcinoma. Braz J Med Biol Res 29:1593-1597 (Pubitemid 126485406)
35. Coughlin SS, Calle EE, Teras LR et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167 (Pubitemid 38747263)
36. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
37. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
38. Cust AE, Allen NE, Kaaks R et al (2007) Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer 120:2656-2664 (Pubitemid 46651288)
39. De Meyts P (1994) The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37(suppl 2):S135-S148
40. DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345-19350
41. DeBerardinis RJ, Lum JJ, Hatzivassiliou G et al (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11-20
42. Dejgaard A, Lynggaard H, Råstam J et al (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52:2507-2512
43. Díez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148: 293-300 EASD, EMEA, ADA, FDA, IDF (http://webcast.easd.org/press/glargine/glargine.htm; http://www.ema.europa.eu "European Medicines Agency update on safety of insulin glargine"; http://forecast.diabetes.org/news/ada-statement-insulin- glargine-and-cancer; http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm169722.htm http://www.idf.org/idf-statement-studies-suggesting-possible-insulin-glargine- cancer-link)
44. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK et al (2010) Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 33:55-60
45. Eliassen AH, Tworoger SS, Mantzoros CS et al (2007) Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 16:161-164 (Pubitemid 46174280)
46. El-Shewy HM, Luttrell LM (2009) Insulin-like growth factor-2/ mannose-6 phosphate receptors. Vitam Horm 80:667-697
47. FDA MedWatch Alert (2008) Exubera (insulin human rDNA origin) inhalation powder. http://www.drugs.com/fda/exubera-insulin-human-rdna-origin-inhalation- powder-12372
48. Feng YH, Velazquez-Torres G, Gully C et al (2010) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med [Epub ahead of print]
49. Flood A, Strayer L, Schairer C et al (2010) Diabetes and risk of incident colorectal cancer in a prospective cohort of women. Cancer Causes Control 21:1277-1284
50. Frasca F, Pandini G, Sciacca L et al (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23-37 (Pubitemid 351998752)
51. Friberg E, Orsini N, Mantzoros CS et al (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365-1374 (Pubitemid 46879010)
52. Furue H, Matsuo K, Kumimoto H et al (2008) Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese. Carcinogenesis 29:316-320 (Pubitemid 351359670)
53. Garofalo C, Surmacz E (2006) Leptin and cancer. J Cell Physiol 207:12-22
54. Gebhardt C, Riehl A, Durchdewald M et al (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205:275-285 (Pubitemid 351281593)
55. Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60:207-221
56. Godsland IF (2009) Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci 118:315-332
57. Goldberg T, Cai W, Peppa M et al (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104:1287-1291 (Pubitemid 39036519)
58. Gonzalez-Angulo AM, Meric-Bernstam F (2010) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16:1695-1700
59. Górska E, Popko K, Winiarska M et al (2009) [Pleiotropic effects of leptin] (in Polish). Pediatr Endocrinol Diabetes Metab 15:45-50
60. Grote VA, Becker S, Kaaks R (2010) Diabetes mellitus type 2-an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 118:4-8
61. Hall GC, Roberts CM, Boulis M et al (2005) Diabetes and the risk of lung cancer. Diabetes Care 28:590-594 (Pubitemid 40315318)
62. Hammond KJ, Pelikan SB, Crowe NY et al (1999) NKT cells are phenotypically and functionally diverse. Eur J Immunol 29: 3768-3781 (Pubitemid 29527827)
63. Hayashi T, Tsujii S, Iburi T et al (2007) Laughter up-regulates the genes related to NK cell activity in diabetes. Biomed Res 28:281-285 (Pubitemid 351425823)
64. Hébert E (2006) Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep 26:7-17
65. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
66. Hemminki K, Li X, Sundquist J et al (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15:548-555
67. Hermann C, Assmus B, Urbich C et al (2000) Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20:402-409 (Pubitemid 30086096)
68. Hirose K, Toyama T, Iwata H et al (2003) Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev 4:239-246
69. Hitosugi T, Kang S, Vander Heiden MG et al (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2:ra73
70. Holly J, Perks C (2006) The role of insulin-like growth factor binding proteins. Neuroendocrinology 83:154-160 (Pubitemid 44578867)
71. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499-2506
72. Houseknecht KL, Baile CA, Matteri RL et al (1998) The biology of leptin: a review. J Anim Sci 76:1405-1420 (Pubitemid 128439681)
73. Hudelist G, Wagner T, Rosner M et al (2007) Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer 14: 1053-1062 (Pubitemid 351252436)
74. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076-2083 (Pubitemid 40897433)
75. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787 (Pubitemid 30648894)
76. Ihle NT, Powis G (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8:1-9
77. Inoue M, Iwasaki M, Otani T et al (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871-1877 (Pubitemid 44455170)
78. International Agency for Research on Cancer (2010). http://www.iarc.fr
79. International Diabetes Federation (2010) http://www.diabetesatlas.org/ content/europe; http://www.idf.org/about-diabetes
80. Jamal MM, Yoon EJ, Vega KJ et al (2009) Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol 15:5274-5278
81. Jee SH, Ohrr H, Sull JW (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194-202 (Pubitemid 40095870)
82. Jenab M, Riboli E, Cleveland RJ et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121:368-376 (Pubitemid 46917707)
83. Jensen M, De Meyts P (2009) Molecular mechanisms of differential intracellular signaling from the insulin receptor. Vitam Horm 80:51-75
84. Jerud ES, Bricard G, Porcelli SA (2006) CD1d-restricted natural killer t cells: roles in tumor immunosurveillance and tolerance. Transfus Med Hemother 33:18-36
85. Jonasson JM, Ljung R, Talbäck M et al (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
86. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
87. Joshi N, Caputo GM, Weitekamp MR (1999) Infections in patients with diabetes mellitus. N Engl J Med 341:1906-1912
88. Kaaks R, Toniolo P, Akhmedkhanov A et al (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92: 1592-1600
89. Kasper JS, Giovanucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:2056-2062 (Pubitemid 44877026)
90. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124:1398-1403
91. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R et al (2003) Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106:90-95 (Pubitemid 36750393)
92. Kellerer M, von Eye Corleta H, Mühlhöfer A et al (1995) Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer 62:501-507
93. Key TJ, Spencer EA, Reeves GK (2010) Symposium 1: overnutrition: consequences and solutions. Obesity and cancer risk. Proc Nutr Soc 69:86-90
94. Kiessling R, Klein E, Pross H et al (1975) "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5:117-121
95. Kiessling R, Petranyi G, Kärre K et al (1976) Killer cells: a functional comparison between natural, immune T-cell and antibodydependent in vitro systems. J Exp Med 143:772-780
96. Kim JW, Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66:8927-8930
97. Kim WY, Jin Q, Oh SH et al (2009) Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res 69:7439-7448
98. Kisfalvi K, Eibl G, Sinnett-Smith J (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69:6539-6545
99. Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005 (Pubitemid 30349423)
100. Landman GW, Ubink-Veltmaat LJ, Kleefstra N et al (2008) Increased cancer mortality in type 2 diabetes (ZODIAC-3). Anticancer Res 28:1373-1375 (Pubitemid 351578882)
101. Landman GW, Kleefstra N, van Hateren KJ et al (2010a) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:322-326
102. Landman GW, Van Hateren KJ, Kleefstra N et al (2010b) The relationship between obesity and cancer mortality in type 2 diabetes: a ten-year follow-up study (ZODIAC-21). Anticancer Res 30:681-682
103. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687 (Pubitemid 41672234)
104. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856-862 (Pubitemid 47106217)
105. Le Marchand L, Wang H, Rinaldi S et al (2010) Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol Biomarkers Prev 19:1471-1477
106. Lee PD, Giudice LC, Conover CA (1997) Insulin-like growth factor binding protein-1 recent findings and new directions. Proc Soc Exp Biol Med 216:319-357
107. Lee JS, Weiss J, Martin JL et al (2003) Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 107:564-570 (Pubitemid 37296116)
108. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127-137 (Pubitemid 36588961)
109. Li D, Yeung SC, Hassan MM et al (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-488
110. Li Q, Kobayashi M, Inagaki H et al (2010) A day trip to a forest park increases human natural killer activity and the expression of anticancer proteins in male subjects. J Biol Regul Homeost Agents 24:157-165
111. Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625
112. London SJ, Yuan JM, Travlos GS et al (2002) Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 94: 749-754 (Pubitemid 34567959)
113. Lowry F (2010) Novel ultra long-acting insulin as effective as insulin glargine. Presented at the American Diabetes Association (ADA) 70th Scientific Sessions: Abstract 34-OR, Orlando (Florida), June 25, 2010
114. Lukanova A, Toniolo P, Akhmedkhanov A et al (2001) A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 92:888-892 (Pubitemid 32467380)
115. Lukanova A, Lundin E, Micheli A et al (2003) Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 14:285-292 (Pubitemid 36649151)
116. Lukanova A, Zeleniuch-Jacquotte A, Lundin E et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108:262-268 (Pubitemid 37541781)
117. Lynch L, O'Shea D, Winter DC et al (2009a) Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 39:1893-1901
118. Lynch LA, O'Connell JM, Kwasnik AK et al (2009b) Are natural killer cells protecting the metabolically healthy obese patient? Obesity 17:601-605
119. Ma J, Giovannucci E, Pollak M et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546-553 (Pubitemid 38559579)
120. Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9:1039-1047
121. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654-662 (Pubitemid 40175840)
122. Maes M, Meltzer HY, Stevens W et al (1994) Natural killer cell activity in major depression: relation to circulating natural killer cells, cellular indices of the immune response, and depressive phenomenology. Prog Neuropsychopharmacol Biol Psychiatry 18:717-730 (Pubitemid 24238877)
123. Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurence in insulin-treated type 2 diabetic patients. Diabetes Care 33:1997-2003
124. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19:17-24
125. Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116:73-78
126. Mazurek S, Boschek CB, Hugo F et al (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15:300-308 (Pubitemid 41058775)
127. Mercer JC, Ragin MJ, August A (2005) Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 37:1337-1343
128. Michaud DS, Wolpin B, Giovannucci E et al (2007) Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16:2101-2109 (Pubitemid 47621187)
129. Montoya CJ, Pollard D, Martinson J et al (2007) Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122:1-14 (Pubitemid 47222606)
130. Moorehead RA, Sanchez OH, Baldwin RM et al (2003) Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 22:853-857 (Pubitemid 36255821)
131. Moretta L, Bottino C, Pende D et al (2005) Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 100:7-13 (Pubitemid 41262028)
132. Muller LM, Gorter KJ, Hak E et al (2005) Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41:281-288 (Pubitemid 41022101)
133. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
134. O'Shea D, Cawood TJ, O'Farrelly C et al (2010) Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS One 5:e8660
135. Pan SY, Johnson KC, Ugnat AM et al (2004) Association of obesity and cancer risk in Canada. Am J Epidemiol 159:259-268 (Pubitemid 38141655)
136. Pedersen PL (2007) Warburg me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39:211-222
137. Pierce BL, Ahsan H (2010) Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 69:193-201
138. Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945-952
139. Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5:617-625 (Pubitemid 39303129)
140. Renehan AG, Zwahlen M, Minder C et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353
141. Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578 (Pubitemid 351232031)
142. Robey RB, Hay N (2006) Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25:4683-4696 (Pubitemid 44187618)
143. Robey RB, Hay N (2009) Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19:25-31
144. Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149:461-471
145. Roder JC, Kiessling R, Biberfeld P et al (1978) Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol 121:2509-2517 (Pubitemid 9075157)
146. Rosenstock J, Fonseca V, McGill JB et al (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52:1971-1973
147. Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin/insulin-like growth factor-1 receptors and G proteincoupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16:2505-2511
148. Schäfer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9:628-638
149. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW (2004) Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 20:369-382 (Pubitemid 39302962)
150. Schoen RE, Tangen CM, Kuller LH et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91:1147-1154 (Pubitemid 29330553)
151. Schupp N, Schinzel R, Heidland A (2005) Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann NY Acad Sci 1043:685-695 (Pubitemid 41123961)
152. Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743-1753
153. Sgambato A, Cittadini A (2010) Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci 14:263-268
154. Siekmeier R, Scheuch G (2008) Inhaled insulin - does it become reality? J Physiol Pharmacol 59(suppl 6):81-113
155. Sieradzki J (2005) Cukrzyca i zespół metaboliczny. In: Szczeklik A (ed) Choroby Wewnȩtrzne. Medycyna Praktyczna, Kraków, vol 1, pp 1179-1215
156. Smyth MJ, Thia KY, Street SE et al (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661-668
157. Sparvero LJ, Asafu-Adjei D, Kang R et al (2009) RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7:17
158. Spitz MR, Barnett MJ, Goodman GE et al (2002) Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 11:1413-1418 (Pubitemid 35340378)
159. Stattin P, Björ O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561-567 (Pubitemid 46354334)
160. Stocks T, Lukanova A, Rinaldi S et al (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 120:2678-2686 (Pubitemid 46651291)
161. Stocks T, Rapp K, Bjørge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6:e1000201
162. Stofkova A (2010) Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 44:25-36
163. Stopper H, Schinzel R, Sebekova K et al (2003) Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 190:151-156 (Pubitemid 36136013)
164. Swann JB, Uldrich AP, van Dommelen S et al (2009) Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113:6382-6385
165. Szkaradkiewicz A, Karpiński TM, Drews M et al (2010) Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol 2010:901564
166. Takahashi K, Iwase M, Yamashita K et al (2001) The elevation of natural killer cell activity induced by laughter in a crossover designed study. Int J Mol Med 8:645-650
167. Tappy L, Lê KA, Tran C et al (2010) Fructose and metabolic diseases: new findings, new questions. Nutrition 26:1044-1049
168. Trayhurn P, Wang B, Wood IS (2008) Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 100:227-235
169. Uribarri J, Cai W, Peppa M et al (2007) Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62:427-433 (Pubitemid 47065712)
170. Uribarri J, Woodruff S, Goodman S et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110:911-916.e12
171. Velcheti V, Govindan R (2006) Insulin-like growth factor and lung cancer. J Thorac Oncol 1:607-610 (Pubitemid 47163945)
172. Vella V, Pandini G, Sciacca L et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245-254 (Pubitemid 34084698)
173. Vigneri P, Frasca F, Sciacca L et al (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103-1123
174. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27:5932-5943
175. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
176. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519-530
177. Waters KM, Henderson BE, Stram DO et al (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169:937-945
178. Wei EK, Ma J, Pollak MN et al (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14:850-855 (Pubitemid 40478547)
179. Werner H, Bruchim I (2009) The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115:58-71
180. Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci 57:932-942 (Pubitemid 30461834)
181. Werner H, Weinstein D, Bentov I (2008) Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 114:17-22 (Pubitemid 351998748)
182. WHO(http://www.who.int/mediacentre/factsheets/fs311/en/index.html, 07.06.2010)
183. Wolpin BM, Meyerhardt JA, Chan AT et al (2009) Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-185
184. Wuenschell GE, Tamae D, Cercillieux A et al (2010) Mutagenic potential of DNA glycation: miscoding by (R)- and (S)-N2-(1-carboxyethyl)-20-deoxyguanosine. Biochemistry 49:1814-1821
185. Yamagishi S, Nakamura K, Inoue H et al (2005) Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. Med Hypotheses 64: 1208-1210
186. Yamagishi S, Matsui T, Nakamura K (2008) Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers. Med Hypotheses 71:259-261
187. Yan SF, D'Agati V, Schmidt AM et al (2007) Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 7:699-710
188. Yeluri S, Madhok B, Prasad KR et al (2009) Cancer's craving for sugar: an opportunity for clinical exploitation. J Cancer Res Clin Oncol 135:867-877
189. Yi HK, Hwang PH, Yang DH et al (2001) Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 37:2257-2263 (Pubitemid 33001298)
190. Zhou XH, Qiao Q, Zethelius B et al (2010) Diabetes, prediabetes and cancer mortality. Diabetologia 53:1867-1876